EGFR and glioblastoma: The whole-exome sequencing data demonstrated that at least one receptor tyrosine kinase (RTK) has altered in almost 67% of glioblastoma overall in 291 patients, alteration is EGFR (57%), PDGFRA (13%), c-MET (1.6%), and FGFR (3.2%), also, 25% and 41% of patients have PI3K mutations and PTEN mutations/deletions, respectively (Wang et al., 2021).